The Netherlandsdsm-firmenich.com
Owner Investor / Financier Operator Developer Technology licensor
dsm-firmenich is a global Swiss–Dutch specialty chemicals and ingredients company formed in 2023 from the combination of DSM and Firmenich. The company develops and produces flavors, fragrances, taste solutions, nutrition and health ingredients, enzymes, vitamins, and aroma molecules for customers in food and beverage, perfumery, home and personal care, dietary supplements, pharmaceuticals, and animal nutrition.
With R&D and manufacturing operations worldwide, dsm-firmenich integrates biotechnology, fermentation, and advanced formulation to deliver functional ingredients and sensorial solutions. The company emphasizes responsible sourcing and energy use across its supply chain and operates with dual headquarters in Switzerland and the Netherlands.
Also known as DSM - Firmenich AG.
chemXplore tracks 16 projects involving dsm-firmenich, of which one is active.
Besides this one, the record holds 15 completed projects.
Closest to start-up first.
The 15 that are completed, on hold or cancelled are in the record. See all 16 in chemXplore →
Exclusive global distribution of GMP‑grade biopharma vitamins for cell culture media; eight B‑vitamin products, multi‑pack sizes and CPHI Milano debut.
New Jakarta Creative Center consolidates labs and co-creation spaces; Karawang expansion adds drying and blending capabilities and reduces CO₂ via electrification and heat recovery.
Boltz foundation models will be applied to ingredient discovery to predict and design scent and flavor molecules using dsm-firmenich’s receptor data, with platform access and embedded researchers.
Patent suit in China alleges unauthorized biotech production of sclareol, seeks injunction and damages; defendants include a sclareol producer and a research institute.
Board chair Thomas Leysen will retire; shareholders will vote on Richard Ridinger at an Extraordinary General Meeting on 19 Oct 2026.
FDA clears bemotrizinol (PARSOL® Shield), the first new U.S. sunscreen active in 25+ years, enabling broad‑spectrum, photostable formulas with low‑concentration efficacy.
Announced Apr 28, 2026: sale of Action Pin (Castets, France), 110 employees, ~€50M sales in 2025; transaction pending regulatory approvals; financial terms undisclosed.
The company aims to enhance growth, EBITDA margins, and cash flow, with a share repurchase program and strategic updates amid ongoing macroeconomic challenges.
active all projects
